Navigation Links
ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
Date:12/5/2007

SAN DIEGO, Dec. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that it has completed patient enrollment in its Phase 2 clinical trial of ANX-510, or CoFactor, for the treatment of advanced breast cancer.

"Data on the primary endpoint in this study, along with overall survival data from our Phase 2b study and available data from our discontinued Phase 3 study, all of which we expect in the second quarter of 2008, will expand our understanding of CoFactor's safety and efficacy," said Evan M. Levine, chief executive officer of ADVENTRX. "By mid-next year we should have greater insight into our ability to develop CoFactor in breast cancer and other indications."

The Phase 2 clinical trial is a single arm, multicenter study to evaluate the safety and efficacy of treatment with CoFactor plus 5-fluorouracil (5-FU) in advanced breast cancer patients who have failed anthracycline and taxane chemotherapies. Patients are treated with CoFactor followed by 5-FU administered by IV bolus weekly for 6 weeks, with tumor and safety assessments every 8 weeks. The primary endpoint for the study is objective response rate as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and secondary endpoints are duration of response, progression free survival, overall survival and incidence and severity of adverse events, as defined by the National Cancer Institute (NCI) Common Terminology Criteria. A total of 32 patients were enrolled in this study.

According to the American Cancer Society, breast cance
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Summary This report presents the ... regarding their Information & Communications Technology (ICT) investment ... allocate their ICT budgets across the core areas ... communications, and consulting. Key Findings ... that X% of respondents anticipate an increase in ...
(Date:9/30/2014)... Investor-Edge has initiated coverage on ... ), Aeterna Zentaris Inc. (NASDAQ: AEZS ), ... Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Exact Sciences Corporation ... be accessed at: http://investor-edge.com/register . On ... 4,505.85, down 0.14%, the Dow Jones Industrial Average finished ...
(Date:9/30/2014)... , Sept. 30, 2014  Come fall, many children, ... or "what" they want to be for Halloween. And, ... look with decorative contact lenses bought without a prescription. ... year that people purchase and wear contact lenses without ... American Eye-Q ® consumer survey, 17 percent of ...
Breaking Medicine Technology:ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 2ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 2Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 4Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 5The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3
(Date:9/30/2014)... OH (PRWEB) September 30, 2014 ... blades sporting the iconic pink ribbon in support of ... a popular month for businesses and non-profits to “go ... worthwhile cause. , AutoTex PINK is a woman-owned company ... wipers. They are committed to partnering with their ...
(Date:9/30/2014)... 30, 2014 Teeth replacement and restoration ... Institute in Oxnard and Thousand Oaks, Calif., is in ... to provide training on full mouth rehabilitation. , “Full ... implants, providing cosmetic dentistry, correcting bite issues, and resolving ... Dr. Jivraj, who has traveled to India to speak ...
(Date:9/30/2014)... 30, 2014 Loffler Companies, an ... technology and services was recognized by BEI as ... (FCE) in 2013. This prestigious rating means that ... time and for an extended period following, optimizing ... 20 years BEI Services has been the trusted ...
(Date:9/30/2014)... In honor of National Breast Cancer Awareness Month ... battles, Incredible Veins, Body & Skin is offering survivors ... , “For cancer patients who receive radiation treatment, ... their skin to accurately aim the radiation on the ... they decide to have their tattoo removed as the ...
(Date:9/30/2014)... 2014 Julie Kuriakose, MD; ... , will discuss how restaurants can become more allergy-friendly ... dietary restrictions at the 2014 Allergy Eats Food ... October 21 in New York City. , “I’m extremely ... to such an engaged industry audience. As food allergies ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Incredible Veins, Body & Skin Takes A Stand Against Breast Cancer With PicoSure® By Cynosure 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3
... This strategy beat out either therapy alone, researchers found ... combination of cognitive behavior therapy plus antidepressant drugs is ... thoughts and behavior in depressed teens, new research shows. ... October issue of the journal Archives of General ...
... Health Inc. (Amex: OPK ),has announced the appointment ... Dr. Goldschmidt is the Senior Vice President for Medical,Affairs ... Miller School of,Medicine. Dr. Goldschmidt formerly served as Chairman ... "We are delighted to welcome an exceptional healthcare ...
... Cottage Hospital,which has served thousands of patients from ... 85 years, has rejoined the Henry Ford,Health System. ... Health,System. In 1998, Cottage became part of the Bon ... part of the joint venture,Henry Ford Health System owned ...
... Summit speakers Kenneth,Thorpe, Ph.D. of Partnership to Fight ... on Health, WASHINGTON, Oct. 1 Overhauling ... candidates, but one top,expert believes any serious proposal ... PhD., helped launch the Partnership to,Fight Chronic Disease ...
... 1 Crdentia Corp. (OTC Bulletin,Board: CRDT), a ... posted an exclusive interview on their website with,Michael ... In the interview, Mr. Yao describes how Crdentia,s ... facility contracts and 1,000 travel nurse,needs nationwide. He ...
... that typically fight bacteria, study finds , MONDAY, Oct. ... urban air pollution, shuts down early immune responses in ... vulnerable to bacteria and other foreign invaders, research shows. ... with increased cardiovascular and pulmonary hospitalizations and deaths, but ...
Cached Medicine News:Health News:Drug Plus Psychotherapy Best Treatment for Depressed Teens 2Health News:OPKO Health Appoints Pascal J. Goldschmidt to Board of Directors 2Health News:OPKO Health Appoints Pascal J. Goldschmidt to Board of Directors 3Health News:Grosse Pointe's Cottage Hospital Joins Henry Ford Health System 2Health News:Grosse Pointe's Cottage Hospital Joins Henry Ford Health System 3Health News:URAC Releases Issue Briefs Examining Stakeholders Views of Care Coordination Along the Healthcare Continuum 2Health News:URAC Releases Issue Briefs Examining Stakeholders Views of Care Coordination Along the Healthcare Continuum 3Health News:Crdentia's National Director of Travel Services Provides an Exclusive Interview on the Growth of Crdentia's Travel Nurse Division 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: